Psoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory musculoskeletal disorder that affects ~0.1% of the population. PsA may severely impact quality-of-life and constitutes a significant economic burden on our health care system. While early effective treatment is deemed essential to prevent irreversible joint damage and functional impairment, not all patients respond to the same disease modifying anti-rheumatic drugs (DMARDs). DMARD options for PsA are rapidly evolving, yet only 50-60% of patients show a satisfactory response to their first-line DMARD therapy. Hence, there is an urgent medical need to predict which patients benefit from a particular treatment. To this end, molecular biomarkers capable of predicting therapeutic response are currently being scrutinized in clinical studies, that together should build a framework for clinical guidelines that improve personalized targeted treatment. In this review new developments within the field of biomarker discovery for predicting therapeutic response to DMARDs in PsA are examined.

中文翻译：

---

新兴的分子生物学标记物可预测银屑病关节炎的治疗反应：文献综述。

银屑病关节炎（PsA）是一种异质性慢性炎症性肌肉骨骼疾病，影响约0.1％的人口。PsA可能会严重影响生活质量，并给我们的医疗保健系统带来巨大的经济负担。尽管早期有效的治疗被认为对于预防不可逆的关节损伤和功能损害至关重要，但并非所有患者对改变抗风湿药（DMARDs）的同一疾病都有反应。用于PsA的DMARD选择正在迅速发展，但是只有50-60％的患者对其一线DMARD治疗表现出满意的反应。因此，迫切需要医疗来预测哪些患者将从特定治疗中受益。为此，目前正在临床研究中研究能够预测治疗反应的分子生物标志物，应该共同为改善个性化靶向治疗的临床指南建立框架。在这篇综述中，研究了生物标志物发现领域中用于预测对PsA中DMARDs的治疗反应的新进展。